Halberd Corp. CEO Interviewed on Money TV; Discusses New Fluorescent Covid-19 Antibody

Rhea-AI Summary

Halberd Corporation (OTC PINK: HALB) announced a new patent-pending Covid-19 fluorescent antibody aimed at rapid virus detection. CEO William A. Hartman discussed the advantages of this test during a Money TV interview, highlighting its potential for real-time monitoring of Covid-19 status, in contrast to existing passports. The test could significantly benefit the travel and entertainment industries. Moreover, Halberd is developing a nasal spray as both a preventive and therapeutic option against Covid-19, while also working on new developments under provisional patents.

Positive

• Introduction of a patent-pending Covid-19 fluorescent antibody for rapid detection.
• Potential to enhance screening at airports and events, aiding the travel industry.
• Development of a nasal spray for Covid-19 prevention and treatment.
• Provisional patents filed for additional developments.

Negative

• None.

Mr. Hartman discusses advantages over existing antibodies

JACKSON CENTER, PA / ACCESSWIRE / November 16, 2020 / Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided information on Halberd's new patent pending Covid-19 fluorescent antibody. This should allow for rapid detection of the virus in infected patients and provide up-to-the-minute status of whether or not an individual has contracted the virus.

This should be much more helpful in preventing the spread of the virus than "Covid-19 Passports" which only represent the recent past condition of the passport holder. This passport is in use in the UK and is being considered for use elsewhere. Halberd's quick test could prove to be a boon to the travel and entertainment industry in screening entrants to airports, train stations, sporting events and large gatherings to determine up to the minute status of the presence of Covid-19 antigens. Development is continuing on the Halberd system to improve the accuracy of results by eliminating false positive or false negative results experienced with competitive tests currently in use.

Hartman added that this fluorescent antibody could not only be used in a diagnostic capacity, but just as with Halberd's initial antibody, could be used as both a preventative measure in a nasal spray delivery context, or as a therapeutic for patients who have contracted the disease. Work is continuing on Halberd's nasal spray preventative against Covid-19 as an alternative to a vaccine.

Hartman alluded to additional new Halberd developments on which a provisional patent has been filed with details to be disclosed soon.

You can view the entire interview video here.

If you would like to be added to our email subscriber list, click here and submit the form.

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC

About Halberd Corporation.

Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus," and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans," and "Nasal Spray to Prevent the Transmission of Covid-19." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/616795/Halberd-Corp-CEO-Interviewed-on-Money-TV-Discusses-New-Fluorescent-Covid-19-Antibody

FAQ

What is Halberd Corporation's new Covid-19 fluorescent antibody?

Halberd Corporation has developed a patent-pending Covid-19 fluorescent antibody that enables rapid detection of the virus.

How will Halberd's new test impact the travel industry?

The test could provide real-time Covid-19 status checks at airports and large gatherings, improving safety and screening efficiency.

What other Covid-19 initiatives is Halberd Corporation working on?

Halberd is also developing a nasal spray that serves both as a preventive measure and therapeutic for Covid-19.

What is the stock symbol for Halberd Corporation?

Halberd Corporation is traded under the stock symbol HALB on the OTC market.

When was Halberd Corporation's new antibody announced?

The announcement was made on November 16, 2020, during an interview with CEO William A. Hartman.